$TELO
Telomir Pharmaceuticals Inc

2024 Q4 Form 10-Q Financial Statement

#000149315224044749 Filed on November 12, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3 2023 Q3
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $691.6K
YoY Change 18591.89%
% of Gross Profit
Research & Development $627.4K $262.6K
YoY Change 138.93% 14.27%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $6.006M $954.1K
YoY Change 529.51% 308.61%
Operating Profit
YoY Change
Interest Expense -$757.2K
YoY Change
% of Operating Profit
Other Income/Expense, Net $15.45K -$757.2K
YoY Change -102.04%
Pretax Income -$1.711M
YoY Change 632.89%
Income Tax
% Of Pretax Income
Net Earnings -$5.991M -$1.711M
YoY Change 250.06% 632.9%
Net Earnings / Revenue
Basic Earnings Per Share -$0.20 -$0.06
Diluted Earnings Per Share -$0.20 -$0.06
COMMON SHARES
Basic Shares Outstanding 29.61M shares 29.61M shares 27.10M shares
Diluted Shares Outstanding 29.61M shares 27.10M shares

Balance Sheet

Concept 2024 Q4 2024 Q3 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.500K
YoY Change
Cash & Equivalents $834.6K $2.452K
Short-Term Investments
Other Short-Term Assets $103.9K
YoY Change
Inventory
Prepaid Expenses $77.35K
Receivables
Other Receivables
Total Short-Term Assets $1.042M $236.3K
YoY Change 340.96%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $5.082M
YoY Change
Total Long-Term Assets $0.00 $5.082M
YoY Change -100.0%
TOTAL ASSETS
Total Short-Term Assets $1.042M $236.3K
Total Long-Term Assets $0.00 $5.082M
Total Assets $1.042M $5.319M
YoY Change -80.41%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $496.0K
YoY Change
Accrued Expenses $13.50K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $1.338M
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $599.9K $3.141M
YoY Change -80.9%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $599.9K $3.141M
Total Long-Term Liabilities $0.00
Total Liabilities $599.9K $3.141M
YoY Change -80.9%
SHAREHOLDERS EQUITY
Retained Earnings -$27.70M
YoY Change
Common Stock $0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $442.1K $2.178M
YoY Change
Total Liabilities & Shareholders Equity $1.042M $5.319M
YoY Change -80.41%

Cashflow Statement

Concept 2024 Q4 2024 Q3 2023 Q3
OPERATING ACTIVITIES
Net Income -$5.991M -$1.711M
YoY Change 250.06% 632.9%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$2.003M
YoY Change 2331.19%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.991M
YoY Change 2388.87%
NET CHANGE
Cash From Operating Activities -2.003M
Cash From Investing Activities
Cash From Financing Activities 1.991M
Net Change In Cash -12.20K
YoY Change 408.33%
FREE CASH FLOW
Cash From Operating Activities -$2.003M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
usd
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
usd
CY2023Q4 us-gaap Cash
Cash
1231 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
435225 usd
CY2023Q4 us-gaap Assets
Assets
4773768 usd
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
707187 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1335564 usd
CY2023Q4 us-gaap Liabilities
Liabilities
1335564 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
17502346 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-14064142 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
3438204 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4773768 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-937278 usd
us-gaap Net Income Loss
NetIncomeLoss
-13634343 usd
dei Amendment Flag
AmendmentFlag
false
CY2024Q3 us-gaap Deferred Offering Costs
DeferredOfferingCosts
usd
CY2024Q3 us-gaap Deferred Costs
DeferredCosts
usd
CY2024Q3 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
usd
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
usd
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
usd
CY2024Q3 us-gaap Travel And Entertainment Expense
TravelAndEntertainmentExpense
usd
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-41952
dei Entity Registrant Name
EntityRegistrantName
Telomir Pharmaceuticals, Inc.
dei Entity Address City Or Town
EntityAddressCityOrTown
Miami
dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
33131
dei City Area Code
CityAreaCode
(813)
dei Local Phone Number
LocalPhoneNumber
864-2558
dei Security12b Title
Security12bTitle
Common Stock, no par value
dei Trading Symbol
TradingSymbol
TELO
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
29609814 shares
CY2024Q3 us-gaap Cash
Cash
834638 usd
CY2023Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
303281 usd
CY2024Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
77347 usd
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
713 usd
CY2024Q3 us-gaap Other Receivables
OtherReceivables
130000 usd
CY2023Q4 us-gaap Other Receivables
OtherReceivables
130000 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
1041985 usd
CY2023Q4 us-gaap Deferred Costs
DeferredCosts
4338543 usd
CY2024Q3 us-gaap Assets
Assets
1041985 usd
CY2024Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
506479 usd
CY2024Q3 us-gaap Other Liabilities
OtherLiabilities
93432 usd
CY2023Q4 us-gaap Other Liabilities
OtherLiabilities
527377 usd
CY2023Q4 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
101000 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
599911 usd
CY2024Q3 us-gaap Liabilities
Liabilities
599911 usd
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000000 shares
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29609814 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29609814 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
28609814 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
28609814 shares
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
28140559 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-27698485 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
442074 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1041985 usd
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5378744 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
102191 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6999981 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
204902 usd
CY2023Q3 us-gaap Travel And Entertainment Expense
TravelAndEntertainmentExpense
589400 usd
us-gaap Travel And Entertainment Expense
TravelAndEntertainmentExpense
370500 usd
us-gaap Travel And Entertainment Expense
TravelAndEntertainmentExpense
1288000 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
262562 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1966258 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1370522 usd
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
6006178 usd
us-gaap Operating Expenses
OperatingExpenses
9336739 usd
us-gaap Operating Expenses
OperatingExpenses
2863424 usd
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001971532
CY2023Q3 us-gaap Interest Income Other
InterestIncomeOther
usd
us-gaap Interest Income Other
InterestIncomeOther
usd
CY2024Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
usd
TELO Noncash Interest Expense
NoncashInterestExpense
usd
us-gaap Share Based Compensation
ShareBasedCompensation
usd
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
usd
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
usd
us-gaap Interest Paid Net
InterestPaidNet
usd
us-gaap Interest Paid Net
InterestPaidNet
usd
TELO Accrued Offering Expense
AccruedOfferingExpense
usd
TELO Issuance Of Warrants On Related Party Line Of Credit
IssuanceOfWarrantsOnRelatedPartyLineOfCredit
usd
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
pure
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
FL
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
87-2606031
dei Entity Address Address Line1
EntityAddressAddressLine1
100 SE 2nd St
dei Entity Address Address Line2
EntityAddressAddressLine2
Ste 2000 #1009
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
627434 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
954153 usd
CY2024Q3 us-gaap Interest Income Other
InterestIncomeOther
15445 usd
us-gaap Interest Income Other
InterestIncomeOther
40939 usd
CY2023Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
757173 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
4338543 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
881225 usd
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
15445 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-757173 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4297604 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-881225 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-5990733 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-1711326 usd
us-gaap Net Income Loss
NetIncomeLoss
-13634343 usd
us-gaap Net Income Loss
NetIncomeLoss
-3744649 usd
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.20
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.20
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.06
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.06
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.46
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.46
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.14
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.14
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29609814 shares
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29609814 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27097294 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
27097294 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29498703 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29498703 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27373844 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
27373844 shares
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
1627567 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-5990733 usd
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4805240 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
442074 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
3889400 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-1711326 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
2178074 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
3438204 usd
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
5832973 usd
us-gaap Net Income Loss
NetIncomeLoss
-13634343 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4805240 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
442074 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-937278 usd
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
910000 usd
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
5950000 usd
us-gaap Net Income Loss
NetIncomeLoss
-3744649 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
2178074 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
2178074 usd
us-gaap Net Income Loss
NetIncomeLoss
-3744649 usd
TELO Noncash Interest Expense
NoncashInterestExpense
13517 usd
us-gaap Share Based Compensation
ShareBasedCompensation
4805240 usd
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
4338543 usd
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
867708 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
102574 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
91806 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
76634 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
963 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4464620 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2772581 usd
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
55583 usd
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
101000 usd
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
130000 usd
us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
-433946 usd
us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
711283 usd
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
1337914 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5832973 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
910000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5298027 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2773614 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
833407 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1033 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1231 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1419 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
834638 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2452 usd
TELO Accrued Offering Expense
AccruedOfferingExpense
124126 usd
TELO Issuance Of Warrants On Related Party Line Of Credit
IssuanceOfWarrantsOnRelatedPartyLineOfCredit
5950000 usd
CY2024Q3 us-gaap Cash
Cash
800000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4500000 usd
us-gaap Proceeds From Secured Lines Of Credit
ProceedsFromSecuredLinesOfCredit
5000000 usd
CY2024Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
100000 usd
CY2023Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
500000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
55667 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
7416 usd
us-gaap Variable Lease Cost
VariableLeaseCost
337111 usd
us-gaap Variable Lease Cost
VariableLeaseCost
1292545 usd
us-gaap Lease Cost
LeaseCost
392778 usd
us-gaap Lease Cost
LeaseCost
1299961 usd
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
400000000 shares
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000000 shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2370170 shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.02
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P10Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
2370170 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5.02
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2370170 shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.02
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
1046335 shares
CY2024Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
4300000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.888 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.901 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.037 pure
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
5.02
CY2024Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5194227 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5194227 shares
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2774057 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2774057 shares

Files In Submission

Name View Source Status
0001493152-24-044749-index-headers.html Edgar Link pending
0001493152-24-044749-index.html Edgar Link pending
0001493152-24-044749.txt Edgar Link pending
0001493152-24-044749-xbrl.zip Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
telo-20240930.xsd Edgar Link pending
telo-20240930_cal.xml Edgar Link unprocessable
telo-20240930_def.xml Edgar Link unprocessable
telo-20240930_lab.xml Edgar Link unprocessable
telo-20240930_pre.xml Edgar Link unprocessable